• Versius granted marketing authorization through FDA’s De Novo process which establishes initial indication for adults undergoing cholecystectomy
  • Globally, Versius is the second most utilized surgical robotic system, with over 26,000 surgical procedures completed across Europe, Latin America, Asia, Middle East and Africa
  • With its unique compact design and portability, Versius can increase surgical options for any care setting in the U.S.